Psoriasis
SFA Therapeutics will begin a Phase 1b trial of patients suffering from Mild to moderate Psoriasis 3Q2020
The study will be conducted in conjunction with Temple University in Philadelphia, PA. Estimated start date is 1 October, 2020
For information contact us at info@sfatherapeutics.com
Images represent results of open label limited exposure
Images are taken after 30 days.
Images of patients taken after 30 days exposure
Data is open label limited exposure
Images of patients taken after 30 days exposure
Data is open label limited exposure
